|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Imfinzi
|
|
gptkbp:analysis
|
Cox proportional hazards model
|
|
gptkbp:analyzes
|
gptkb:durvalumab
gptkb:Dr._Scott_J._Antonia
|
|
gptkbp:business_model
|
gptkb:battle
|
|
gptkbp:clinical_trial
|
NC T02125461
|
|
gptkbp:collaborations
|
gptkb:European_Organization_for_Research_and_Treatment_of_Cancer
gptkb:healthcare_organization
gptkb:American_Society_of_Clinical_Oncology
|
|
gptkbp:collection
|
patient questionnaires
|
|
gptkbp:committee
|
gptkb:battle
|
|
gptkbp:completed
|
gptkb:2019
|
|
gptkbp:criteria
|
previous immunotherapy
stage IIINSCLC patients
|
|
gptkbp:duration
|
up to 12 months
|
|
gptkbp:events
|
at least 24 months
|
|
gptkbp:finale_date
|
quality of life assessment
progression-free survival at 12 months
|
|
gptkbp:focuses_on
|
gptkb:healthcare_organization
|
|
gptkbp:follows
|
clinical visits
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PACIFIC trial
|
|
gptkbp:is_studied_in
|
completed
multicenter, randomized, double-blind
|
|
gptkbp:is_tested_for
|
gptkb:III
|
|
gptkbp:launched
|
gptkb:2015
|
|
gptkbp:location
|
multiple countries
|
|
gptkbp:marketed_as
|
gptkb:Imfinzi
|
|
gptkbp:members
|
placebo group
|
|
gptkbp:notable_work
|
improved overall survival
improved progression-free survival
|
|
gptkbp:participants
|
overall survival
progression-free survival
|
|
gptkbp:population
|
adults
|
|
gptkbp:products
|
gptkb:durvalumab
|
|
gptkbp:provides_information_on
|
gptkb:battle
|
|
gptkbp:published_year
|
gptkb:2018
|
|
gptkbp:recorded_by
|
gptkb:battle
|
|
gptkbp:regulatory_compliance
|
gptkb:battle
|
|
gptkbp:result
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
pneumonitis
|
|
gptkbp:sponsor
|
gptkb:temple
|
|
gptkbp:student_enrollment
|
over 700 patients
|
|
gptkbp:target_audience
|
patients with unresectable stage IIINSCLC
|
|
gptkbp:treatment
|
durvalumab vs placebo
|
|
gptkbp:vision
|
gptkb:battle
|
|
gptkbp:website
|
hospitals worldwide
|
|
gptkbp:year
|
gptkb:2017
|